DelSiTech Ltd’s Post

CDSCO launched series of digital initiatives to streamline pharmaceutical regulations: DCGI He further informed that another big initiative is the Online National Drug License System (ONDLS). Branded as the "One Nation-One Drug Licensing System”, this initiative offers a digital portal managed by CDSCO for uniform drug licensing across all States and Union Territories. It standardizes requirements and interpretations, maintains a comprehensive database of licenses, and enables prompt verification, ensuring no discrepancies or anomalies in the licensing process. #CDSCO #drug #initiative

Some really interesting discussions today at the IPHA annual conference, really highlighted the streangh and vibrancy of the pharmaceutical sector in Ireland but also the challenges posed by the implementation of CSDR and the need for a more efficient reimbursement process. #IPHA

By proactively addressing intellectual property considerations and implementing key strategies in the alliance agreement, pharmaceutical companies can minimize the risks associated with collaborative efforts and foster a more secure and mutually beneficial partnership.

💊 Mass tort lien resolution in pharmaceutical cases can be a complex process, but it’s essential for ensuring plaintiffs receive the compensation they deserve. ⚖️ Our latest blog breaks down the key challenges and offers expert insights on best practices for managing liens effectively. ➡️ Read more about the intricacies of lien resolution and how to navigate this crucial step in pharmaceutical mass tort cases. https://bit.ly/4gLtQ7b #lienresolution #masstorts #attorneys

Seven contracts, seven headaches. Trax turned a tangled mess into a single, efficient solution for a global pharmaceutical company. Learn their secret: https://hubs.li/Q02kr2Hr0 #Partnership #Trax #GlobalSupplyChain

💊 "In the next part of Our series, we discuss how the Pharma industry generates revenue through Exclusive and Non-exclusive Licensing systems! 💼  From royalties to product distribution, discover all the key revenue channels that power pharmaceutical innovation. 🚀✨". To watch full video Visit this link:-https://lnkd.in/gtdpiew5 . . #PharmaRevenue #PharmaLicensing #ExclusiveLicense #NonExclusiveLicense #RevenueStreams #PharmaIndustry #HealthcareInnovation #LicensingDeals #Royalties #Pharmaceuticals #Sr4IPR #BusinessGrowth #Licensing

What are duplicate discounts and how do they impact the various stakeholders in the pharmaceutical supply chain? In this article for The Antitrust Prescription, Rajshri Suresh and Tram Nguyen discuss these discounts to highlight the importance of and considerations for addressing them. #340B #economicconsulting #PharmaAntitrust #EEAntitrustPrescription https://lnkd.in/eQpQDb7S

Read our commentary on the latest development around the European Commission's cartel investigation in relation to active pharmaceutical ingredient N-Butylbromide Scopolamine/Hyoscine (SNBB): a Statement of Objections sent to Alchem. Alchem was the only non-settling party when the Commission concluded a cartel settlement agreement with six other pharmaceutical companies in October 2023. 🔗https://lnkd.in/eAUBwgSd Michael Clancy | Peter L'Ecluse | Catherine Longeval | Koen T'Syen #lifesciences #competitionlaw #cartels #hybridprocedure

Confidential reimbursement amounts in Germany only attractive for individual cases: For the first time, the law also establishes the regulatory possibility of agreeing confidential reimbursement amounts in Germany, which can create new opportunities for pharmaceutical companies to act but are linked to demanding challenges, which we discuss in our new blog: https://lnkd.in/eVnQPiTy #marketacess #pricing #reimbursement

Today the Opinion of the AG was delivered in case C-248/23 Novo Nordisk. The case deals with the possibility to reduce the VAT for payments made by pharmaceutical companies to state authorities in relation to medicinal products sold (such as clawback and cost volume). The dispute is set once more in Hungary - previously the CJEU gave a ruling in the case C-717/19 Boehringer Ingelheim dealing also with the qualification of pharmaceutical contributions as price reductions. The current Opinion brings new nuances which could shape the qualification of such contributions as price reductions for VAT purposes. Let’s see if the CJEU would endorse the concepts in the AG Opinion. #pharma #pwcromania #cjeu #vat